STAT3 and lung carcinoma: Previous studies have found that the abnormal activation of STAT3 in the development of KRAS mutant lung cancer, which will be attenuated under anti-IL-6 therapy, suggesting a tight association between IL-6/STAT3 signaling and inflammation in KRAS-activated tumorigenesis (56, 57).